A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology.

T-cell skin lymphomas are more common than B-cell skin lymphomas. Cutaneous T-cell lymphoma (CTCL) occurs when a mutation causes the cell to divide too quickly and stay alive too long. The ...

In a small percentage of patients, T-cell accumulation is so extensive that disfiguring nodules and tumors develop (see Figure 4). As the tumors grow they may ulcerate and lead to considerable ...

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...

Investigators found that denileukin diftitox, which targets the interleukin-2 receptor, achieves objective response rates in 44% of patients with cutaneous T-cell lymphoma, with a median duration ...

Cutaneous T-cell lymphoma is a group of rare blood cancers that affects the skin. Nine patients have been enrolled and treated with HyBryte over up to 54 weeks. Also Read: Soligenix Kickstarts ...

Despite the statistically significant result achieved in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that the ...

My research is aimed at developing an improved understanding of new therapies for patients with several less-common types of lymphoma, including T cell lymphomas, cutaneous (skin) lymphomas, Hodgkin ...

utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active ...

Phototherapy involves the use of ultraviolet light for the treatment of skin disease and many dermatologists have phototherapy units in their offices. With these units, ultraviolet light of ...

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology. Cutaneous T ...